Noodles & Company’s Guidance Reflects Strong Consumer Demand For Its Products, Says Analyst
Stephens analyst Joshua Long reiterated an Overweight rating on the shares of Noodles & Company (NASDAQ:NDLS) with a price target of $7.…
Logitech Analyst Sees Investors Unlikely To Engage Pending Signs Of Bottoming
Citigroup analyst Asiya Merchant maintains Logitech International SA (NASDAQ:LOGI) with a Buy and lowers the price target from $70 to $60. Logitech…
Analysts Cheer Nuvei Post Upbeat Q4; 20%+ Ex-Crypto Organic Growth Validates Its Moats And Market Share Gains
Credit Suisse analyst Timothy Chiodo upgrades Nuvei Corp (NASDAQ:NVEI) from Neutral to Outperform and raises the price target from $37 to $45.…
5 MongoDB Analysts Are Disappointed: ‘Tepid Growth’ Overshadows Q4 Revenue Beat
Shares of MongoDB Inc (NASDAQ: MDB) continued to slide in early trading on Thursday, after the company reported disappointing revenue guidance.
Susquehanna Reiterates Positive on Nutanix, Maintains $34 Price Target
Susquehanna analyst Mehdi Hosseini reiterates Nutanix (NASDAQ:NTNX) with a Positive and maintains $34 price target.
Asana Rallies Off Q4 Earnings: 6 Analysts Break Down The Report
Shares of Asana Inc (NYSE: ASAN) were surging Thursday in the wake of the software platform's fourth-quarter results. Here's what the Street has to say.
Susquehanna Reiterates Positive on Keysight Techs, Maintains $208 Price Target
Susquehanna analyst Mehdi Hosseini reiterates Keysight Techs (NYSE:KEYS) with a Positive and maintains $208 price target.
Susquehanna Reiterates Neutral on Coherent, Maintains $45 Price Target
Susquehanna analyst Mehdi Hosseini reiterates Coherent (NYSE:COHR) with a Neutral and maintains $45 price target.
Stephens & Co. Reiterates Overweight on Noodles, Maintains $7 Price Target
Stephens & Co. analyst Joshua Long reiterates Noodles (NASDAQ:NDLS) with a Overweight and maintains $7 price target.
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight and maintains $6 price target.